Neurobo Pharmaceuticals Stock Total Debt
| NRBODelisted Stock | USD 1.89 0.11 5.50% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
Neurobo |
Neurobo Pharmaceuticals Company Total Debt Analysis
Neurobo Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Neurobo Pharmaceuticals Total Debt | 203 K |
Most of Neurobo Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Neurobo Pharmaceuticals has a Total Debt of 203 K. This is 99.99% lower than that of the Biotechnology sector and 99.94% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Neurobo Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobo Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics of similar companies.Neurobo Pharmaceuticals is currently under evaluation in total debt category among its peers.
Neurobo Fundamentals
| Return On Equity | -1.61 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | (1.18 M) | |||
| Shares Outstanding | 8.62 M | |||
| Shares Owned By Insiders | 65.23 % | |||
| Shares Owned By Institutions | 12.71 % | |||
| Number Of Shares Shorted | 34.27 K | |||
| Price To Earning | (1.44) X | |||
| Price To Book | 1.57 X | |||
| Revenue | 7 K | |||
| EBITDA | (15.88 M) | |||
| Net Income | (12.47 M) | |||
| Cash And Equivalents | 8.85 M | |||
| Cash Per Share | 9.96 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (10.8 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (4.29) X | |||
| Target Price | 26.67 | |||
| Beta | -0.28 | |||
| Market Capitalization | 20.33 M | |||
| Total Asset | 22.78 M | |||
| Retained Earnings | (108.27 M) | |||
| Working Capital | 16.55 M | |||
| Current Asset | 21.62 M | |||
| Current Liabilities | 11.75 M | |||
| Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
Moving against Neurobo Stock
| 0.72 | BA | Boeing | PairCorr |
| 0.7 | CSCO | Cisco Systems | PairCorr |
| 0.69 | MMM | 3M Company | PairCorr |
| 0.68 | JPM | JPMorgan Chase | PairCorr |
| 0.56 | GE | GE Aerospace | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |